Knowledge at the heart of leadership
Welcome to Liftstream - Life Sciences Recruitment

Liftstream is an executive search recruitment company in the life sciences sector

Executive and Board Director Appointments in Oncology and Rare Diseases

Third Rock Ventures portfolio company, Voyager Therapeutics, a gene therapy player in the field of CNS based out of Cambridge, Mass. have appointed Michael Higgins to the Board of Directors. Mr. Higgins is an experienced biotechnology executive and is currently an entrepreneur-in-residence at Polaris Partners. Previously, he served as chief operating officer and chief financial officer at Ironwood Pharmaceuticals, Inc. from 2003 through 2014. In 2014, Mr. Higgins was named the Boston Business Journal’s CFO of the Year. Mr. Higgins worked at Genzyme Corporation, with which Voyager Therapeutics now has a partnership, from 1997 through 2003 in a variety of leadership roles, including vice president of corporate finance and vice president of business development. While at Genzyme, he was involved with multiple business units, including Cell Therapy, Gene Therapy and Orphan Diseases.

Read the full article…

Posted in Executive Appointments | Tagged , , , , , , , , , , , , , , , , | Leave a comment

Executive Recruitment Round-up October 2014

Authored by James Sheppard

Read the full article…

Posted in Executive Appointments, Orphan Drugs and Rare Diseases, Pharmaceutical business, Recruitment Market | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

Dr John Martin – Gilead – Executive Leadership Series

Authored by James Sheppard

Read the full article…

Posted in Pharmaceutical business | Tagged , , , , , , , , , , , , , , , | Leave a comment

Soaring biotech equity heightens recruitment challenges

Authored by Karl Simpson

Read the full article…

Posted in M&A Finance and Funding, Pharmaceutical business, Recruitment Market | Tagged , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

PTC Therapeutics opts for conditional approach in Duchenne

Authored by Paul Foster

Read the full article…

Posted in Orphan Drugs and Rare Diseases | Tagged , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

Gilead Expands Oncology Offering with Purchase of YM Bioscience

In mid-December Gilead Sciences announced they had signed a deal to purchase the Canadian company YM Bioscience for $510m in cash ($2.95 per share). The purchase gives Gilead access to a second experimental drug to treat a rare blood and immune cell disorder.

Read the full article…

Posted in Orphan Drugs and Rare Diseases | Tagged , , , | Leave a comment

Shareholder Value Creation Through Effective Clinical and Regulatory Management

Authored by Karl Simpson

Read the full article…

Posted in Pharmaceutical business | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

Pharma’s emerging markets push creates talent gap

Liftstream looks at how the emerging markets is placing demands on talent and creating gaps in expertise within key functions like regulatory affairs.

Read the full article…

Posted in General, Pharmaceutical business | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment




Contact Us

   Liftstream Ltd.
67 Grosvenor Street
London
W1K 3JN

   Tel: ​+44 (0)20 3178 5864
   info@liftstream.com

Register your CV

Apply for sector specific vacancies or request a confidential discussion



Registered in England No: 5009233
VAT: 843679292

Follow Us





Sitemap